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Background: Pseudomonas aeruginosa is an important nosocomial pathogen, commonly causing infections in
immunocompromised patients. The aim of this study was to examine the genetic relatedness of metallo-beta-
lactamase (MBL) producing carbapenem resistant Pseudomonas aeruginosa clinical isolates collected from 2 tertiary
hospitals in Cairo, Egypt using Multi Locus sequence typing (MLST).
Methods: Phenotypic and genotypic detection of metallo-beta-lactamase for forty eight non-duplicate carbapenem
resistant P. aeruginosa isolates were carried out. DNA sequencing and MLST were done.
Results: The blaVIM-2 gene was highly prevalent (28/33 strains, 85%) among 33 MBL-positive P.aeruginosa isolates.
MLST revealed eleven distinct Sequence Types (STs). A unique ST233 clone producing VIM-2 was documented by
MLST in P.aeruginosa strains isolated from Cairo university hospitals. The high prevalence of VIM-2 producers was
not due to the spread of a single clone.
Conclusions: The findings of the present study clearly demonstrate that clones of VIM-2 positive in our hospitals
are different from those reported from European studies. Prevalence of VIM-2 producers of the same clone was
detected from surgical specimens whereas oncology related specimens were showing diverse clones.
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Pseudomonas aeruginosa, an opportunistic pathogen, is
an important cause of infection in patients with im-
paired immune systems [1]. P. aeruginosa is a prime ex-
ample of a species that has continually evolved such that
many strains are extensively drug resistant—i.e., resistant
to all standard anti-pseudomonal antibiotics (carbapen-
ems and aminoglycosides) and sensitive only to colistin
[2]. Nowadays, intensive clinical use of carbapenems has
caused the presence of carbapenem resistant P. aeruginosa
populations [3] and an increase in carbapenem resist-
ance by acquisition of different mechanisms, such as* Correspondence: mai_zafer@hotmail.com
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unless otherwise stated.hyperproduction of chromosomal AmpC beta-lactamase,
overexpression of efflux systems, alteration or lack of
outer membrane proteins (such as porin OprD), and pro-
duction of carbapenemases [4]. The advent of mobile
MBL genes heralded a new chapter in resistance; class 1
integrons, the mobile genetic structures that carry MBL
genes, also carry genes encoding determinants of resist-
ance to aminoglycosides and other antibiotics, and thus
confer extensive drug resistance [5]. MBL gene blaVIM-2
was first reported in P. aeruginosa in France in 2000,
but the earliest recorded case was in Portugal in 1995
[6]. VIM-2 has emerged as a dominant MBL variant
worldwide. MultiLocus sequence typing (MLST) has
identified international clonal complexes (CCs) respon-
sible for the dissemination of MBL-producing P.aeruginosa,his is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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Zafer et al. BMC Infectious Diseases  (2015) 15:122 Page 2 of 7particularly in European countries [7], in Japan [8],
Singapore, and Brazil.
The aim of this study was to examine the genetic re-
latedness of MBL producing P. aeruginosa strains isolated
from two hospitals in Cairo, Egypt.
Methods
Bacterial isolates
Forty eight non-duplicate carbapenem resistant P. aeru-
ginosa isolates were obtained from clinical specimens
submitted for bacteriological testing from hospitalized
in-patients admitted to Kasr Al Aini Hospital (KAA) and
National Cancer Institute (NCI), Cairo University, Egypt
from January 2011 to January 2012. KAA School of
Medicine and NCI are tertiary hospitals belonging to
Cairo University, Egypt. The study was approved by the
Ethics Committee of Cairo University and an informed
consent was obtained from all patients receiving treat-
ment and participating in the study.
Isolate identification
Initial identification and susceptibility testing was done
using VITEK 2 (bioMerieux, Marcy l’E’toile, France) au-
tomated machine. Genotypic identification was carried
out by PCR amplification and sequence determination of
16S rDNA previously described by Spilker et al. [9]. The
identified strains were stored in glycerol broth cultures
at - 70°C.Table 1 List of primers used in this study












blaGIM TCGACACACCTT GGT CTG AA blaGIM
AACTTCCAACTT TGCCATGC amplification
blaSPM AAAATCTGGGTACGCAAA CG blaSPM
ACATTATCCGCTGGAACAGG amplification
blaSIM TAC AAG GGATTCGGCATCG blaSIM
TAATGG CCTGT CCCATG TG amplification
intI1 intI1
Int-1-F GCA TCC TCG GTT TTC TGG amplification
Int-1-R GGT GTG GCG GGC TTC GTGAntimicrobial susceptibility testing
Susceptibility testing was done by the disc diffusion
method of the Clinical and Laboratory Standards Institute,
[10] with discs from Oxoid (Oxoid ltd., Basin Stoke,
Hants, England). MICs were determined with E-test strips
(bioMerieux, Marcy L’Etoile, France). P. aeruginosa ATCC
27853 was used as a control throughout.
Phenotypic detection of MBLs
E-test MBL strips were in accordance with the manufac-
turer’s instructions to seek MBL production. A no less than
eight-fold reduction in imipenem MIC in the presence of
EDTA, or a phantom zone, was taken as a positive result.
Detection of MBL-encoding genes and integrase genes
blaVIM-2, blaIMP-1, blaSIM, blaGIM, blaSPM, blaNDM-2 and
intI1 were amplified for P.aeruginosa isolates using
primers listed in Table 1 according to the previous proto-
cols [11-15]. Negative and positive controls were involved
in all PCR experiments. Five microliters of reaction mix
containing PCR product were analysed by electrophoresis
in 0.8% (w/v) agarose (Fermentas, Lithuania).
DNA sequencing
Amplified products of blaVIM-2 were purified using a
QIAquick PCR Purification Kit (Qiagen, Crawley, UK)
and sequenced in both directions using the ABI Prism
3700 DNA Sequencer (Applied Biosystems, Foster City,Expected PCR product Reference
956 bp Spilker et al. [9]
740 bp Yan et al. [11]
801 bp Frasson et al. [12]
and sequencing
984 bp Kaase et al. [13]
477 bp Ellington et al. [12]
271 bp Ellington et al. [12]
570 bp Ellington et al. [12]
457 bp Shibata et al. [15]
and sequencing
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comparison with the sequences in GenBank (http://blast.
ncbi.nlm.nih.gov/Blast.cgi).
Multi-locus sequence typing (MLST)
PCR and sequencing of the recognized chromosomal
markers (7 housekeeping genes) acsA, aroE, guaA, mutL,
nuoD, ppsA, and trpE were done [16]. The nucleotide se-
quences of these genes were compared with the sequences
submitted to the MLST database to determine the allelic
numbers and sequence types.
The collection of MLST data on P. aeruginosa is avail-
able on http://pubmlst.org/paeruginosa/. MLST was per-
formed for twenty isolates, representatives of the blaVIM-2
gene identified. All these isolates were imipenem resistant,
MBL producing and VIM-2 positive. An isolate from each
hospital was selected randomly for comparison.
Results
Of the 48 carbapenem resistant P.aeruginosa isolates, 33
(68.7%) were confirmed to be MBL producers. Of the 48
P.aeruginosa isolates, 21 isolates were from wound, 12
were from urine, 9 were from sputum,4 were from blood
and two were from ear swab; 16 (48.5%), 8 (24.2%), 6
(18.1%), 2 (6.1%) and 1 (3.0%) produced MBL, respectively.
Each of MBL positive strains and their MIC results are
summarized in Table 2.
Of the 33 MBL isolates, MBL encoding genes blaVIM
was identified in 28(85%) isolates, blaNDM was identi-
fied in 2 (6.1%) isolates and blaIMP was identified in
only one (3.0%) isolate. In this work MBL blaGIM,
blaSIM, and blaSPM allele were not detected. Twenty
nine (87.8%) of the MBL-producing isolates were posi-
tive for class 1 integron. All the VIM-2 producing iso-
lates had the class 1 integron. All isolates were resistant
to imipenem (MIC ≥ 8 μg/ml). Sequencing of intrinsic
blaVIM confirmed that the nucleotide sequences obtained
were identical to genes for VIM-2 for P.aeruginosa. Simi-
larly, the nucleotide sequences of class І integron also co-
incided with the results predicted by the PCR analyses.
Eleven distinct STs were identified. Results of STs ana-
lyzed are recorded in Table 2. Antibiotic susceptibility
result for 33 MBL producing P.aeruginosa is given in
Table 3.
Discussion
This study clearly demonstrates that carbapenem non-
susceptible P. aeruginosa is present in Egypt in isolates
of different origins mainly isolated from surgical wards
with high prevalence of VIM-2 positivity in MBL produ-
cing P.aeruginosa isolates. The ability of MBL-producing
P. aeruginosa to reach high level endemicity in certain
settings has, indeed, been established, [5] and in these
cases, MBLs can outpace loss of oprD and up-regulatedefflux pumps as leading factors causing reduced carba-
penem susceptibility; distinct clones even unfolding their
potential for causing outbreaks [17]. Our results revealed
that 33 (68.7%) of 48 carbapenem resistant P.aeruginosa
isolates produced MBL. This study demonstrated an in-
creasing prevalence of MBL. Similarly high prevalence of
MBL producing P.aeruginosa was detected in the Egyptian
study where 82% were MBL producers [18]. In another
Egyptian study 32.3% MBL producing P.aeruginosa was
observed which is lower than our findings [19]. In the
present study, VIM-2 was the most frequently detectable
gene among the different MBL genes investigated; the per-
cent of 85% among carbapenem-resistant MBL producing
P. aeruginosa was detected. This finding was supported by
results of previous studies demonstrating VIM-2 as the
most dominant MBL implicated in imipenem resistant P.
aeruginosa and confers the greatest clinical threat [20].
Worldwide, VIM-2 is the dominant MBL gene associated
with nosocomial outbreaks due to MBL-producing P.
aeruginosa [21]. Since MBL-producing isolates can cause
serious infections that are difficult to treat, their presence
in various hospitals in Egypt is of nationwide concern.
The absence of new agents for the treatment of infections
caused by these bacteria may lead to treatment failures
with increased morbidity and mortality. A class 1 integron
carries the integrase gene (intI1), which encodes the site-
specific recombinase responsible for cassette insertion. In
our study class 1 integron was confirmed in 29 (87.8%) of
MBL producing P.aeruginosa. This result is consistent
with findings from Malaysia in which they suggested that
the class 1 integron is the most abundant type of integron
present among the clinical isolates of P.aeruginosa in
Malaysia [22].
MDR P.aeruginosa isolates, resistant to almost all β-
lactams, aminoglycosides and quinolones, often ascribed
to epidemic clones (ST235 or ST111), have been detec-
ted in hospitals worldwide, mainly within ICU [23]. The
increasing prevalence of MDR P. aeruginosa isolates is a
global health problem, because of the limitation in clin-
ical treatment options. All the VIM-producing isolates in
this study belonged to international clones. In this study
the results of MLST showed that VIM-2 type MBL car-
bapenem resistant P. aeruginosa specimens isolated from
surgical wards of Kasr Al Aini hospital showed similarity
in which ST233 which was a part of the internationally
dominant clonal cluster CC233 was detected in 7/15
isolates indicating health care acquired transfer of P.
aeruginosa could occur and should be prevented, an
increased risk of cross-transmission and high antimicrobial
pressure might have favoured clonal spread. Additionally,
patients who have the potential to facilitate dissemination
of MDR organisms between hospitals subsequently, might
serve as important reservoirs and transmission sources,
stressing the importance of hand hygiene compliance, and
Table 2 Isolation details, VIM-2 gene results, MICs and sequence type of 33 P.aeruginosa MBL positive isolates
Isolate Duration of
episode in days
Sample Hospital VIM-2 NDM-1 IMP-1 PM PTc TZ TZL CI AK GM IP CT Sequence
type (ST)
1 21 Wound KAA + - - ≥256 16 ≥256 ≥256 2 12 3 ≥32 ≥256
2 9 Blood KAA + - - 12 64 8 3 ≥32 16 ≥256 ≥32 ≥256
3 36 Wound KAA + + - 8 64 64 24 ≥32 ≥256 12 ≥32 ≥256 233
4 30 Wound KAA + - - 4 3 6 2 ≥32 ≥256 ≥256 ≥32 32 233
5 13 Wound KAA + - - 4 3 6 1.5 ≥32 ≥256 ≥256 ≥32 32
6 8 Wound KAA + + - 64 ≥256 ≥256 ≥256 ≥32 ≥256 ≥256 ≥32 ≥256 233
7 5 Wound KAA + - - 24 ≥256 ≥256 192 ≥32 ≥256 12 ≥32 ≥256
8 10 Wound KAA + - - 6 96 96 24 0.094 4 2 ≥32 ≥256
9 10 Urine KAA + - - ≥256 3 ≥256 ≥256 ≥32 32 12 ≥32 ≥256 303
10 9 Blood KAA + - - 2 4 1.5 ≥32 2 2 ≥32 16 ≥256
11 75 Sputum KAA + - - ≥256 ≥256 ≥256 ≥256 ≥32 ≥256 32 ≥32 ≥256
12 4 Wound KAA + - - 6 24 8 16 ≥32 ≥256 1.5 ≥32 ≥256 198
13 30 Urine NCI + - - ≥256 ≥256 ≥256 ≥256 ≥32 ≥256 ≥256 ≥32 ≥256 629
14 10 Sputum NCI - - - ≥256 24 ≥256 ≥256 1 6 2 ≥32 ≥256
15 30 Wound NCI - - + 16 24 16 4 ≥32 12 ≥256 ≥32 ≥256
16 46 Wound NCI + - - ≥256 ≥256 48 8 ≥32 96 ≥256 ≥32 ≥256 233
17 22 Sputum NCI + - - 6 12 12 2 ≥32 6 ≥256 ≥32 ≥256 507
18 70 Sputum NCI - - - ≥256 4 ≥256 ≥256 ≥32 96 32 ≥32 ≥256
19 65 Sputum NCI + - - ≥256 ≥256 ≥256 96 0.094 96 32 ≥32 ≥256 406
20 120 Sputum NCI + - - 64 32 12 2 ≥32 16 ≥256 ≥32 ≥256 303
21 54 Wound KAA + - - 8 16 24 4 ≥32 48 ≥256 ≥32 ≥256 233
22 27 Wound KAA + - - 16 ≥256 ≥256 ≥256 ≥32 128 32 ≥32 ≥256 274
23 7 wound KAA + - - 256 ≥256 ≥56 256 ≥32 ≥256 32 ≥32 ≥256 884
24 45 Urine KAA + - - 8 12 ≥256 4 0.064 8 ≥256 ≥32 ≥256 738
25 150 urine KAA + - - ≥256 ≥256 ≥256 128 ≥32 48 32 ≥32 ≥256 274
26 75 Wound KAA + - - ≥256 ≥256 ≥256 ≥256 ≥32 ≥256 ≥256 ≥32 ≥256 683
27 21 Urine KAA + - - 16 ≥256 ≥256 32 0.064 8 32 ≥32 ≥256 990
28 45 Urine KAA - - - 64 ≥256 ≥256 ≥256 0.064 32 32 ≥32 ≥256
29 240 Urine KAA + - - 2 4 12 2 0.125 4 2 ≥32 ≥256 233
30 180 Urine KAA + - - 2 4 8 1.5 0.125 4 2 ≥32 ≥256 233
31 21 Wound KAA + - - 8 128 6 24 0.094 6 2 ≥32 ≥256
32 30 Wound KAA - - - 12 32 2 8 0.064 6 2 ≥32 ≥256
33 21 Ear swab KAA + - - 6 6 ≥256 8 3 ≥32 128 16 ≥32 233
PM= cefepime, PTc = piperacillin/tazobactam, TZL = ceftazidime/clavulanic acid, TZ = ceftazidime, CI = ciprofloxacin, AK = amikacin, GM= gentamicin, IP = imipenem,
CT = cefotaxime.
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shown from specimens isolated from NCI where 5 distinct
sequence types were observed. This diversity could be due
to previous empirical intake of antibiotics or misuse. ST
233 VIM-2 producing P.aeruginosa was detected in one
isolate imported from Ghana in a study done in Norway
and Sweden in which the two international clonal com-
plexes CC111 and CC235 associated with MBL-producing
P. aeruginosa isolates were dominant [24]. In previous
studies from different Russian states, VIM-2 positive ST
235 was the predominant isolated type that has rapidlyspread throughout Russia, Belarus and Kazakhastan via
clonal dissemination. The authors were not able to prove
the reason for spread of VIM-2 positive ST 235 but ex-
plained that inappropriate use of antibiotics and poor
adherence to infection control practice could be among
the reasons [25]. Although P.aeruginosa clinical isolates
are seldom typed and therefore under-reported, ST235
association with VIM-2 seems Europe centered, and has
been reported in Belgium, Croatia, Serbia, and, more re-
cently, Greece [26]. In other parts of Europe ST 111 were
the major sequence type detected in MBL producing
Table 3 Resistance patterns of 33 P. aeruginosa MBL positive strains
Isolate Type of specimen Antibiotic disk diffusion susceptibility test
Imipenem Augmentin Cefuroxime Cefoperzone Ceftazidime Ciprofloxacin Meropenem
1 Wound R R R R R R R
2 Blood R R R R R R R
3 Wound R R R R R R R
4 Wound R R R R R S R
5 Wound R R R R R R R
6 Wound R R R R R S R
7 Wound R R R R R R R
8 Wound R R R R R S R
9 Urine R R R R R R R
10 Blood R R R R R R R
11 Sputum I R R R R I R
12 Wound R R R R R R R
13 Urine R R R R R R R
14 Sputum R R R R R I R
15 Wound R R R R R R R
16 Wound R R R R R R R
17 Sputum R S R R S R R
18 Sputum R R R S S R R
19 Sputum R R R R R S R
20 Sputum R R R R R R R
21 Wound R R R R R R R
22 Wound R R R R R S R
23 wound R R R R R S R
24 Urine R R R R R R R
25 Urine R R R R R I R
26 Wound R R R R R I R
27 Urine R R R R R R R
28 Urine R R R R R S R
29 Urine R R R R R S R
30 Urine R R R R R R R
31 Wound R R R R R S R
32 Wound R R R R R R R
33 Ear swab R R R R R R R
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Isolate Antibiotic disk diffusion susceptibility test
Amikacin Sulperazone Levofloxacine Gentamicin Norfloxacine Tazocin Ceftriaxone Polymixin B
1 R R R R R R R S
2 R I R R R R R S
3 R R R R R R R S
4 R R R R S R R S
5 R R R R R R R S
6 R R R R R S R S
7 R R R R R R R S
8 R R R R R R R S
9 R R R R R R R S
10 S R R S R R R S
11 R R R R R I R S
12 R R R R R R R S
13 S R R R R R R S
14 S R R S R S R S
15 S S R R R R R R
16 R R R R R R R S
17 R R R R R R R S
18 R R R R R R S S
19 S R R S R R R S
20 R R R R R R R S
21 R R R R R R R S
22 R R S R R R R S
23 R R S R R R R S
24 R R R S R R R S
25 R R R R R R R S
26 R R R R R R R S
27 R R R R R S R S
28 R R S R S R R S
29 R R R R R R R S
30 R R R R R R R S
31 R R S R R R R S
32 R R R S R S R R
33 S R R R R R R S
Table 3 Resistance patterns of 33 P. aeruginosa MBL positive strains
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spread [27]. Thus it seems that different clones could
be detected from different geographical areas.
Conclusions
The findings of the present study clearly demonstrate
that clones of VIM-2 positive in our hospitals are differ-
ent from those reported from European studies as none
of our isolates revealed ST 235. Prevalence of VIM-2
producers of the same clone was detected from surgical
specimens whereas oncology related specimens were show-
ing diverse clones. Similar ST seems to be transmitted dueto poor adherence to infection control policies which
necessitate efforts for more strict abidance to infection
control regulations. Different clones from different spe-
cialty hospitals in our study requiring further investi-
gations to explain the relation of diversity of ST types to
cause of resistance.
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